HC Wainwright Issues Positive Forecast for TRDA Earnings

Entrada Therapeutics, Inc. (NASDAQ:TRDA) – Equities research analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for Entrada Therapeutics in a report released on Monday, March 2nd. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($1.12) per share for the quarter, up from their prior forecast of ($1.20). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Entrada Therapeutics’ current full-year earnings is $1.12 per share. HC Wainwright also issued estimates for Entrada Therapeutics’ Q2 2026 earnings at ($1.30) EPS, Q3 2026 earnings at ($1.12) EPS, Q4 2026 earnings at ($0.96) EPS, FY2026 earnings at ($4.49) EPS, Q1 2027 earnings at ($0.80) EPS, Q2 2027 earnings at ($0.72) EPS, Q3 2027 earnings at ($0.79) EPS, Q4 2027 earnings at ($0.87) EPS and FY2027 earnings at ($3.18) EPS.

Other research analysts also recently issued research reports about the company. Guggenheim upgraded Entrada Therapeutics to a “strong-buy” rating in a report on Wednesday, February 11th. Roth Mkm set a $13.00 price objective on Entrada Therapeutics in a report on Thursday, November 6th. Oppenheimer assumed coverage on Entrada Therapeutics in a research report on Wednesday, January 28th. They issued an “outperform” rating and a $21.00 price objective on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Entrada Therapeutics in a report on Monday, December 29th. Finally, Wall Street Zen upgraded shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $18.50.

Entrada Therapeutics Stock Performance

Shares of Entrada Therapeutics stock opened at $12.50 on Thursday. The stock has a market capitalization of $478.50 million, a price-to-earnings ratio of -3.61 and a beta of -0.12. The company has a fifty day moving average of $10.99 and a 200-day moving average of $8.62. Entrada Therapeutics has a 52-week low of $4.93 and a 52-week high of $12.93.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.94) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.38. The company had revenue of $1.30 million for the quarter, compared to analysts’ expectations of $7.41 million. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%.

Institutional Trading of Entrada Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Invesco Ltd. boosted its position in shares of Entrada Therapeutics by 41.1% in the fourth quarter. Invesco Ltd. now owns 41,033 shares of the company’s stock worth $422,000 after purchasing an additional 11,958 shares during the period. XTX Topco Ltd lifted its position in shares of Entrada Therapeutics by 26.4% in the fourth quarter. XTX Topco Ltd now owns 117,668 shares of the company’s stock valued at $1,210,000 after acquiring an additional 24,589 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Entrada Therapeutics by 9.5% in the fourth quarter. Wellington Management Group LLP now owns 1,044,758 shares of the company’s stock worth $10,740,000 after acquiring an additional 90,339 shares during the period. Sphera Funds Management LTD. bought a new stake in Entrada Therapeutics in the 4th quarter valued at $1,140,000. Finally, Quadrature Capital Ltd boosted its position in shares of Entrada Therapeutics by 13.5% during the 4th quarter. Quadrature Capital Ltd now owns 20,318 shares of the company’s stock valued at $209,000 after acquiring an additional 2,424 shares during the last quarter. 86.39% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Entrada Therapeutics

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: HC Wainwright maintains a “Buy” rating and a $20 price target on TRDA, highlighting material upside vs. the current share price and providing bullish analyst support for investors. Article Title
• Positive Sentiment: HC Wainwright slightly raised its Q1 2026 EPS forecast (less negative: from ($1.20) to ($1.12)), a modest near-term improvement that can be read as a small positive signal about expense or timing assumptions. Article Title
• Neutral Sentiment: HC Wainwright published a full set of quarterly and FY2027 forecasts (Q1–Q4 2026/2027 and FY2026/2027) — useful for modeling but largely informational until company results or guidance confirm assumptions. Article Title
• Neutral Sentiment: Reported short-interest data is effectively zero/ambiguous (0 shares reported), so it does not appear to be a material driver of intraday moves or a source of short-squeeze risk. Article Title
• Negative Sentiment: HC Wainwright lowered several near-term EPS estimates — notably cutting FY2026 from ($4.21) to ($4.49) and trimming Q2–Q4 2026 and Q3 2026 estimates — signaling larger expected losses next year and raising short-term execution/financing concerns. Article Title

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.